Overall reductions in the individual parameters of the metabolic syndrome subjects were significantly higher in Group I. Cholesterol level decreased from 11 % to 27.2 % ( P < 0.001 ) , triglyceride levels decreased from 24 % to 55 % , VLDL and LDL levels reduced by 60 % & 54 % respectively after 18 months of therapy .